Vestcor Inc Has $14.75 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Vestcor Inc decreased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 20,706 shares of the biopharmaceutical company's stock after selling 884 shares during the quarter. Vestcor Inc's holdings in Regeneron Pharmaceuticals were worth $14,750,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the stock. Rakuten Securities Inc. increased its position in shares of Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 15 shares during the last quarter. Bronte Capital Management Pty Ltd. increased its position in shares of Regeneron Pharmaceuticals by 11.5% during the 4th quarter. Bronte Capital Management Pty Ltd. now owns 152,783 shares of the biopharmaceutical company's stock worth $108,832,000 after purchasing an additional 15,741 shares during the last quarter. Avantax Advisory Services Inc. increased its position in shares of Regeneron Pharmaceuticals by 33.1% during the 4th quarter. Avantax Advisory Services Inc. now owns 1,624 shares of the biopharmaceutical company's stock worth $1,157,000 after purchasing an additional 404 shares during the last quarter. AGF Management Ltd. increased its position in shares of Regeneron Pharmaceuticals by 281.2% during the 4th quarter. AGF Management Ltd. now owns 1,277 shares of the biopharmaceutical company's stock worth $910,000 after purchasing an additional 942 shares during the last quarter. Finally, Wealthfront Advisers LLC increased its position in shares of Regeneron Pharmaceuticals by 68.5% during the 4th quarter. Wealthfront Advisers LLC now owns 15,990 shares of the biopharmaceutical company's stock worth $11,390,000 after purchasing an additional 6,501 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $689.50 on Thursday. The stock has a fifty day moving average price of $696.62 and a 200-day moving average price of $841.12. The company has a market cap of $75.38 billion, a price-to-earnings ratio of 18.01, a PEG ratio of 2.34 and a beta of 0.27. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $642.00 and a fifty-two week high of $1,211.20.

Remove Ads

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion during the quarter, compared to analysts' expectations of $3.76 billion. During the same quarter in the previous year, the firm earned $11.86 EPS. Regeneron Pharmaceuticals's revenue was up 10.3% on a year-over-year basis. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.51%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 2.30%.

Analysts Set New Price Targets

Several brokerages have recently commented on REGN. Leerink Partnrs upgraded Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 5th. TD Cowen reduced their target price on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a research note on Tuesday, February 4th. Truist Financial reduced their target price on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating for the company in a research note on Wednesday, January 8th. Bernstein Bank reduced their target price on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Finally, Piper Sandler reduced their target price on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating for the company in a research note on Monday, January 27th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.